NLRP3 and atrial fibrillation: In a pivotal study, Wu et al. [122] investigated the functional significance of the NLRP3–CASP1–galectin-3 axis in diabetic AF using a rabbit model and assessed the therapeutic potential of glibenclamide—an antidiabetic agent with known NLRP3-inhibitory properties.